Key Takeaways
- H1 profit already exceeds full-year FY24: Net profit reached ₹111 crores in H1 FY25 against ₹102 crores for all of FY24, driven by a multi-year R&D and premiumization strategy.
- Kharif season disrupted, Rabi set up well: A dry July delayed sprays, then excessive August rains triggered ₹35 crores of herbicide returns, but full reservoirs and ample moisture point to a strong Rabi.
- Maharatna volume grew despite returns: Premium-brand volumes rose ~9% even after the returns, while generic volumes fell ~13% partly by design as the sales force pivots toward higher-margin products.
- Raw material prices have bottomed: Management sees prices at 20-25 year lows and believes further declines are almost impossible, removing a source of inventory write-down risk.
- What to watch next quarter: Whether the promised Rabi demand materializes into top-line recovery, the pace of new Maharatna launches, and any margin follow-through from the ~14.5% Q2 EBITDA level.
Season & Demand Environment
- Kharif was a tale of two extremes: July was dry, delaying sprays, then continuous rainfall after mid-August caused further disruption. The season extended into October on Brown Plant Hopper incidence, but the volume impact was decent, not large.
- Sales returns concentrated in herbicides: ₹35 crores of returns hit Q2, almost entirely in the Maharatna (Navratna) herbicide portfolio, not generics. Management clears the market fully rather than leaving stock with the channel, a practice it says competitors do not follow.
- Rabi setup is unusually strong: All reservoirs are full, soil moisture is ample, and farmers are expected to sow choicest crops. Acreage looks decent for paddy, wheat, maize (corn increasing significantly), pulses and sugarcane.
- Top-line suffered 10% but recovery is expected: Management believes a large part of the shortfall will be recovered, though maintaining the 15% growth guidance is difficult and only some growth is now promised for FY25.
Aggarwal: "some prices or like the products have touched the bottom actually, which I have never seen in the last 20, 25 years of my experience. Going below this is almost impossible."
Premiumization & Product Strategy
- Maharatna is the engine: Volume grew ~9% in Q2 despite the returns. The strategy is to bring new technology, train the network and consumers, and shift the sales force away from generics toward premium products.
- Generic decline is partly deliberate: The ~13% volume drop in generics reflects both a tail-cutting strategy (exiting low-margin SKUs) and industry dynamics.
- Launch pipeline is active: Four launches happened in October, including Torry Super (herbicide), which is expected to become a Maharatna product. One more among the four will also reach Maharatna status. A further 2-3 launches are planned in H2, taking the total to 6-7.
- Exclusive Nissan product coming: A new exclusive product from Nissan is expected to launch around March, with registration anticipated in November-December and certification taking 2-3 months thereafter.
- Partnership model is mixed: Some products have multiple partners by design to capture more market share; new discovery products will be exclusive to IIL.
Aggarwal: "We are trying to create our monopoly — monopoly in the sense that by bringing the new patented compounds, by making the new patented products. So the focus is now moving into that direction."
Margins & Profitability
- H1 profitability leap: The company earned ₹111 crores in H1 FY25, exceeding the ₹102 crores earned in the entire full year FY24. Management attributes this to a planned, multi-year R&D-focused strategy.
- Q2 EBITDA margin reached ~14.5%: H1 margin stood at ~12.5%, with Q1 margins repeated and improved upon in Q2. Management was conservative on forward guidance but said there will be growth.
- Raw material tailwind is real: Prices have bottomed out and are firming slightly, with only 1-3% normal fluctuations. No stress is visible.
- Inventory and working capital improving: Inventory days improved this quarter and management expects the momentum to continue. Receivables increased seasonally (Q2 has more sales, less collection) but collections are fine.
Aggarwal: "from INR102 crores in the complete full year, we have bagged the profit of INR111 crores this year, actually in the half year itself."
Kaeros Acquisition & B2B
- Acquisition closed at ₹7 crores: Kaeros had revenue of ₹45 lakh last year and more than 8 import registrations from China. The business only started in February after two years of R&D.
- Strategic rationale is twofold: First, it allows import of ready-made technicals to compete without importing technicals from abroad (except Japan). Second, in the B2B pack-to-pack segment, using the Kaeros brand avoids competition with IIL's own partners.
- Second-brand opportunity exists but is undecided: Management sees potential to launch a second brand through Kaeros since IIL's own network expansion is limited, but the plan is still under consideration.
- B2B showing some recovery: No large order book, but routine orders are coming in well and supplies are being made. The company is trying to introduce more products, including some Maharatna products, into the B2B segment.
Aggarwal: "I was never keen to give it to Insecticides India and wanted to establish a new company. But when I had the plans to establish a big business, so there was a guidance that this should be done under Insecticides India itself."
Biologicals & Future Bets
- Biologicals is a conviction call: Management believes biologicals is the future and that all technologies will run in parallel. A separate R&D center is operational, working with micros, consortia, national and international companies, and research institutes.
- New plant being planned: A dedicated IIL Biologicals plant is planned on a 7-acre site, and the R&D team has been expanded.
- Launches are small and incremental for now: One launch is coming this month (October), with small, small launches expected going forward. Management is waiting for the opportune time for a breakthrough.
- Exports order book is full: Orders collected already match last year's sales, and some Latam business is beginning this year.
Aggarwal: "We are focusing a lot on biologicals because I believe that biologicals is the future. And in future, all the technologies are going to run parallelly."
Brand & Competitive Positioning
- Tractor Brand is the long-term asset: Management's stated vision is to make the Tractor Brand so strong that consumers choose it over any other product without question. The brand already has a large following and trust, and the goal is to take it to the next level with newer, more reliable solutions.
- Competitive confidence is explicit: Management claims capability to beat everybody and anybody in the market, though it does not want to compare performance with peers.
- Training and technology investment continues: A new training module is being launched for the entire team (not just sales), and the CRM program is being improved through automation and technological advancements.
Aggarwal: "The idea is we have created a large following for the Tractor Brand and people have developed their trust... Now we have to take it to the next level so that we can make Tractor Brand bigger so that nobody has questions while selecting a product because if it is a Tractor Brand, they should say yes."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Top-line recovery | Large part of the 10% Kharif shortfall to be recovered; "there will be some growth" in FY25 but 15% guidance is difficult | FY25 full year |
| H2 growth | Growth expected in both top line and bottom line; "I'll not say that there will be a decline" | H2 FY25 |
| Rabi season strength | Very, very strong Rabi season expected on full reservoirs and ample moisture | Rabi season |
| International business | Will cross last year's achievement; order book already full to match last year's sales | FY25 |
| New product launches | 6-7 total launches in H2, including Torry Super and one more expected to reach Maharatna status | H2 FY25 |
| Exclusive Nissan product launch | Registration expected November-December, certificate in 2-3 months, launch around March | March 2025 |
| Biologicals plant | New plant planned on 7-acre site; R&D team expanded | No date given |
| Profitability direction | Expected to increase as company moves further into patented compounds | No date given |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue from operations | ₹627 cr, compared to ₹696 cr in Q2 FY24 |
| EBITDA | ₹90 cr, up 9% YoY from ₹82 cr |
| EBITDA margin | 14.4%, compared to 11.8% in Q2 FY24 |
| PAT | ₹61 cr, up 16% YoY |
| H1 FY25 revenue from operations | ₹1,284 cr |
| H1 FY25 EBITDA | ₹128 cr |
| H1 FY25 EBITDA margin | 12.5% |
| H1 FY25 PAT | ₹111 cr, up ~34% YoY; exceeded full-year FY24 PAT of ₹102 cr |
| Maharatna products volume growth | ~10% YoY, despite sales returns |
| Generic products volume degrowth | ~13% YoY |
| Overall price decline | ~10% YoY |
| Sales returns booked in Q2 | ₹35–40 cr, majorly from herbicides |
| Expected additional sales returns in Q3 | up to ₹10–15 cr of insecticide |
| Premium products share of B2C sales | 68%, generics at 32% |
| B2C sales share | 84% of total revenue; B2B 14%; exports 2% |
| Product segment mix | Insecticide 61%, herbicide 21%, fungicide 15%, others 4% |
| FY25 top-line growth guidance | 15% growth target; management indicated maintaining it may be difficult |
| Industry volume growth estimate | ~4–5% (management estimate, not confirmed) |
| Upcoming product launches in H2 FY25 | 6–7 launches, including Torry Super; 4 launching in November |